Le Lézard
Classified in: Health
Subjects: TDS, FVT

SFA Therapeutics, Inc. To Present At Bio Investors Forum


PHILADELPHIA, Oct. 18, 2019 /PRNewswire/ -- SFA Therapeutics, Inc. announced today that their CEO, Dr. Ira Spector, will update the company's clinical development plans for several new therapeutic agents they have derived from the human microbiome. The presentation will be delivered as part of the prestigious Bio Investors Forum on October 23rd at 9:45AM in the Elizabethan Room of the Westin St. Francis Hotel in San Francisco, CA.

About SFA Therapeutics

SFA Therapeutics, Inc. is a bio-pharmaceutical company focused on new human-microbiome-based advancements in the treatment of inflammatory diseases, targeting NF-kB and RAS. Chronic inflammation has been implicated in a wide range of diseases, including HCC, Psoriatic Arthritis, Rheumatoid Arthritis, Lupus (SLE), Inflammatory Bowel Disease (IBD), Crohn's Disease, Liver Disease and relapse/recurrence in AML and CML.  SFA currently has five drugs under development, and is targeting psoriasis, Hepatitis B and Hepatocellular Carcinoma (liver cancer) with their lead assets.

SFA's small-molecule drugs are derived from natural substances produced in the human microbiome and enable a new platform for developing safer treatments for inflammatory diseases. SFA's drug development platform has been exclusively licensed from Temple University to SFA Therapeutics in Jenkintown, PA. Please visit www.sfatherapeutics.com to learn more.

Contact:
Ira Spector, PhD
[email protected]
2675841080

PRLog ID: www.prlog.org/12794356

 

SOURCE SFA Therapeutics, Inc.


These press releases may also interest you

at 11:45
SummaryProduct: Henna cones Issue: Chemical hazard / Product safety What to do: Stop using and selling them immediately and dispose of them in regular household garbage Who this is for: General public / Industry; Retail, Importers IssueHealth Canada...

at 11:30
The "Global Antibody Therapeutic Market: Focus on Format, Disease Area, Route of Administration, End Users, Region, and Competitive Landscape - Analysis and Forecast, 2024-2033" report has been added to  ResearchAndMarkets.com's offering. The global...

at 11:30
XtalPi Inc., a leading global technology company in integrating artificial intelligence (AI) and robotics to advance the discovery of groundbreaking medicine and innovative materials, announced today the launch of its proprietary comprehensive solid...

at 11:25
Manifest Technologies, Inc., developer of an AI-powered computational neuro-imaging platform for CNS disease, today unveiled the company after completing its initial funding and partnership with a top five global pharmaceutical company. Today, over...

at 11:08
Sunwave Health, a leader in healthcare technology, proudly announces the launch of MARA, a patent-pending, innovative AI Agent designed to transform the landscape of behavioral health documentation. Since its launch on October 25, 2023, MARA has...

at 11:04
MelliCell Inc. has been awarded a U.S. National Science Foundation (NSF) Small Business Innovation Research (SBIR) grant for $275,000 to conduct research and development (R&D) work on "Industrial Scale Technology for Drug Development in Mature Human...



News published on and distributed by: